Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study
Open Access
- 9 January 2026
- journal article
- Published by Wiley in Hematological Oncology
- Vol. 44 (1) , e70168
Abstract
Primary effusion lymphoma (PEL) is a rare and aggressive B‐cell non‐Hodgkin lymphoma (NHL) that predominantly affects patients with human immunodeficiency virus infection and is strongly associated with human herpes virus 8 (HHV‐8) infection. Due to its rarity, the current understanding of PEL's epidemiology and management is largely derived from case reports and small retrospective studies. Using the SEER‐17 database, we conducted a retrospective analysis of adults with pathologically confirmed primary effusion lymphoma diagnosed between 2001–2021. Patients were stratified into two time periods (2001–2010 and 2011–2021) to assess temporal trends. Age‐adjusted incidence rates, relative survival (RS), overall survival (OS), and lymphoma‐specific survival (LSS) were calculated using flexible parametric survival models. Competing risk analysis was performed to evaluate cumulative incidence of lymphoma‐specific death. Among 236 patients (median age 51 years, 88% male), 82 were diagnosed in 2001–2010 and 154 in 2011–2021. Age‐adjusted incidence rates increased from 1.0 to 1.6 cases per 10,000,000 person‐years between periods ( p = 0.004). Five‐year RS improved from 21% to 37%, with median OS increasing from 4 to 12 months. On multivariable analysis, the more recent period showed significant improvements in OS (HR = 0.65; 95% CI, 0.44–0.97) and LSS (HR = 0.56; 95% CI, 0.36–0.86), with reduced cumulative incidence of lymphoma‐specific death (HR = 0.49; 95% CI, 0.33–0.74). In our population‐level analysis of PEL, we report a significant improvement in survival outcomes between 2001–2021, likely reflecting advances in both lymphoma treatment and HIV management. However, despite these improvements, OS remains low underscoring the need for prioritizing these patients to clinical trials with novel therapies.Keywords
This publication has 24 references indexed in Scilit:
- Prognosis in primary effusion lymphoma is associated with the number of body cavities involvedLeukemia & Lymphoma, 2012
- Remission After Radiotherapy for a Patient With Chemotherapy-Refractory HIV-Associated Primary Effusion LymphomaJournal of Clinical Oncology, 2008
- Successful Reduced-Intensity Conditioning Allogeneic HSCT For HIV-Related Primary Effusion LymphomaTransplantation and Cellular Therapy, 2008
- A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapyAnnals of Oncology, 2006
- Comparison of Human Herpes Virus 8 Related Primary Effusion Lymphoma with Human Herpes Virus 8 Unrelated Primary Effusion Lymphoma-Like Lymphoma on the Basis of HIV: Report of 2 Cases and Review of 212 Cases in the LiteratureActa Haematologica, 2006
- Prognostic Factors and Outcome of Human Herpesvirus 8–Associated Primary Effusion Lymphoma in Patients With AIDSJournal of Clinical Oncology, 2005
- KSHV-Positive Solid Lymphomas Represent an Extra-Cavitary Variant of Primary Effusion LymphomaAmerican Journal of Surgical Pathology, 2004
- Clinical Features and Outcome of Primary Effusion Lymphoma in HIV-Infected Patients: A Single-Institution StudyJournal of Clinical Oncology, 2003
- The Natural History and Molecular Heterogeneity of HIV-Associated Primary Malignant Lymphomatous EffusionsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virusBlood, 1996